Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-2162 in Healthy Subjects
NCT07195604Phase 1Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Sep 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of HRS-2162 in neuromuscular blockade (NMB) (7 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoint: Incidence and severity of adverse events at Day 7. Started Sep 2025; status: completed.
02
Drugs
HRS-2162
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT07195604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07195604.